Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 55 of the 60 references it cites were found in a registry or an index; 26 of the 31 sources its claims cite were checked for support.

Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization

Open access
Maruyama, Kohei, Shimizu, Yuki, Nomura, Yumi, Oh-hara, Tomoko, Takahashi, Yuki, Nagayama, Satoshi, Fujita, Naoya, Katayama, Ryohei · 2025 · npj Precision Oncology

Abstract

KRAS-specific inhibitors have shown promising antitumor effects, especially in non-small cell lung cancer, but limited efficacy in colorectal cancer (CRC) patients. Recent studies have shown that EGFR-mediated adaptive feedback mediates primary resistance to KRAS inhibitors, but the other resistance mechanisms have not been identified. In this study, we investigated intrinsic resistance mechanisms to KRAS inhibitors using patient-derived CRC cells (CRC-PDCs). We found that KRAS-mutated CRC-PDCs can be divided into at least an EGFR pathway-activated group and a PI3K/AKT pathway-activated group. In the latter group, PDCs with PIK3CA major mutation showed high sensitivity to PI3K+mTOR co-inhibition, and a PDC with Her2 amplification with PIK3CA minor mutation showed PI3K-AKT pathway dependency but lost KRAS-MAPK dependency by cytoplasmic localization of KRAS. In the PDC, Her2 knockout restored KRAS plasma membrane localization and KRAS inhibitor sensitivity. The current study provides insight into the mechanisms of primary resistance to KRAS inhibitors, including aberrant KRAS localization.

Overview

CoChat Summary

TL;DR

KRAS-mutant colorectal cancer patient-derived cells (CRC-PDCs) show intrinsic resistance to KRAS inhibitors through either EGFR-mediated MAPK reactivation or PI3K/AKT pathway activation. In a Her2-amplified, PIK3CA-mutant KRAS-G12C PDC, cytoplasmic KRAS localization reduces KRAS–MAPK dependency; Her2 knockout restores plasma membrane KRAS and sotorasib sensitivity.

Key findings

  • KRAS inhibitor treatment completely suppressed KRAS-GTP for 48 h, but p-ERK suppression was temporary and recovered by 48 h; all PDCs sustained p-AKT for 48 h, and all PDCs maintained >50% viability after KRAS knockdown, unlike SW1463.
  • EGFR-family inhibitors plus KRAS inhibitor suppressed viability in more than half of CRC-PDCs; afatinib plus sotorasib/MRTX1133 produced continuous p-ERK suppression and cleaved PARP, and sotorasib plus cetuximab suppressed tumor growth in JC288 xenografts (N = 4; sotorasib 100 mg/kg, cetuximab 1 mg/body, 5 days/week).
  • JC261 (KRAS-G12C, PIK3CA K111E, ERBB2-amplified) was resistant to KRAS–EGFR inhibition; ERBB2 was 16-fold amplified, Her2/p-Her2 and p-AKT were high, and PI3K+mTOR inhibition reduced viability, with triple PI3K/mTOR/KRAS-G12C inhibition inducing robust apoptosis.
  • Her2 knockout in JC261 reduced p-Her3/p-AKT, increased p-ERK and GTP-KRAS, restored KRAS plasma membrane localization, and recovered sensitivity to sotorasib and trametinib; parental JC261 and Her2-amplified KRAS-WT JC69 showed cytoplasmic KRAS.

Methods

  • Established KRAS-G12C and -G12D CRC-PDCs from surgically resected specimens; used cell viability assays (CellTiter-Glo), immunoblotting, Ras pull-down, siRNA knockdown, CRISPR-Cas9 Her2 knockout, immunofluorescence, 3D co-culture, and xenograft models.
  • Drug screening used a library of 91 targeted drugs with KRAS inhibitors; genomic profiling used target sequencing of 12 surgically resected CRC tumors and normal paired samples with KRAS-G12C or -G12D mutations, plus exome sequencing and CNVkit analysis.
  • In vivo: JC288 and JC261 cells were subcutaneously injected into BALB/c-nu/nu mice; once tumors reached ~150 mm³, mice (N = 4) received sotorasib (100 mg/kg) or sotorasib plus cetuximab (1 mg/body) for 5 days/week; tumor volume calculated as 0.5 × length × width² and analyzed by Mann–Whitney U-test.

Limitations

  • Stated: Her2-amplified CRC is infrequent (~2 or 3% of CRC), and the authors could not establish Her2-overexpressed KRAS-G12C cells, so the detailed mechanism of aberrant KRAS localization was not identified.
  • Stated: the genomic analysis had a small sample size, with 42% KRAS/PIK3CA concomitant mutations versus 26.7% in MSK-IMPACT.
  • Evident from the text: the link between Her2 amplification and cytoplasmic KRAS localization remains correlative; the paper notes that farnesyltransferase-related gene mRNA was unchanged and that KRAS localization was not altered by afatinib, leaving the responsible Her2-interacting or scaffold proteins unresolved.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41698-024-00793-6

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Single inhibition of mutant KRAS was not sufficient to abrogate cell viability in CRC-PDCs. a, b Evaluation of sensitivity to KRAS inhibitors. Cells were treated with 1 µM of sotorasib or 30 nM of MRTX1133 for 72 h. Cell viability was detected by CellTiter-Glo assay, and the relative cell viability to the non-treated condition was calculated. Data were expressed as mean ± SD. c Confirmation of the KRAS downstream signal in KRAS inhibitor treatment. KRAS-G12C and KRAS-G12D CRC cell lines were exposed to 1 µM of sotorasib or 100 nM of MRTX1133 treatment. The cell lysates were collected at each time point and immunoblotted to detect the indicated antibodies (left). d Evaluation of KRAS dependency in KRAS-mutated PDCs. The cell viability was measured by CellTiter-Glo assay, and the relative cell viability to si-ctrl cells was calculated. Data were expressed as mean ± SD.
Fig. 1 Single inhibition of mutant KRAS was not sufficient to abrogate cell viability in CRC-PDCs. a, b Evaluation of sensitivity to KRAS inhibitors. Cells were treated with 1 µM of sotorasib or 30 nM of MRTX1133 for 72 h. Cell viability was detected by CellTiter-Glo assay, and the relative cell viability to the non-treated condition was calculated. Data were expressed as mean ± SD. c Confirmation of the KRAS downstream signal in KRAS inhibitor treatment. KRAS-G12C and KRAS-G12D CRC cell lines were exposed to 1 µM of sotorasib or 100 nM of MRTX1133 treatment. The cell lysates were collected at each time point and immunoblotted to detect the indicated antibodies (left). d Evaluation of KRAS dependency in KRAS-mutated PDCs. The cell viability was measured by CellTiter-Glo assay, and the relative cell viability to si-ctrl cells was calculated. Data were expressed as mean ± SD.CC BY-NC-ND · PubMed Central
Fig. 2 Mutant KRAS and EGFR inhibition markedly suppressed cell viability in CRC-PDCs. a Inhibitor library screening of KRAS-mutated PDCs. Cells were co-cultured with the indicated inhibitors (bottom), 1 µM of sotorasib or 100 nM of MRTX1133 for 72 h. Cell viability was detected by CellTiter-Glo assay, and relative cell viability to a single treatment of KRAS inhibitors was calculated. b Combination efficacy of KRAS-G12C inhibitor (sotorasib) plus Erbb family inhibitor (afatinib). KRAS-G12C PDC (JC288) was exposed to 1 µM of sotorasib with or without the indicated concentrations of afatinib for 72 h. Cell viability was detected by CellTiter-Glo assay, and relative cell viability to non-treated condition was calculated. c Combination efficacy of the KRAS-G12D inhibitor (MRTX1133) plus afatinib. KRAS-G12D PDC (JC117) was exposed to 100 nM of MRTX1133 with or without the indicated concentrations of afatinib for 72 h. Cell viability was detected by CellTiter-Glo assay, and relative cell viability to non-treated conditions was measured. d, e Immunoblotting analysis of the KRAS inhibitor plus afatinib. JC288 and JC117 cells were treated with sotorasib or MRTX1133 for the indicated time. Cell lysates were immunoblotted to detect the indicated antibodies (left).
Fig. 2 Mutant KRAS and EGFR inhibition markedly suppressed cell viability in CRC-PDCs. a Inhibitor library screening of KRAS-mutated PDCs. Cells were co-cultured with the indicated inhibitors (bottom), 1 µM of sotorasib or 100 nM of MRTX1133 for 72 h. Cell viability was detected by CellTiter-Glo assay, and relative cell viability to a single treatment of KRAS inhibitors was calculated. b Combination efficacy of KRAS-G12C inhibitor (sotorasib) plus Erbb family inhibitor (afatinib). KRAS-G12C PDC (JC288) was exposed to 1 µM of sotorasib with or without the indicated concentrations of afatinib for 72 h. Cell viability was detected by CellTiter-Glo assay, and relative cell viability to non-treated condition was calculated. c Combination efficacy of the KRAS-G12D inhibitor (MRTX1133) plus afatinib. KRAS-G12D PDC (JC117) was exposed to 100 nM of MRTX1133 with or without the indicated concentrations of afatinib for 72 h. Cell viability was detected by CellTiter-Glo assay, and relative cell viability to non-treated conditions was measured. d, e Immunoblotting analysis of the KRAS inhibitor plus afatinib. JC288 and JC117 cells were treated with sotorasib or MRTX1133 for the indicated time. Cell lysates were immunoblotted to detect the indicated antibodies (left).CC BY-NC-ND · PubMed Central
Fig. 3 KRAS-G12C inhibitor with cetuximab combination showed promising effects in PDCs in 3D and in vivo experiments. a Evaluation of sotorasib plus cetuximab combination efficacy in a 3D culture. b JC288 cells were subcutaneously transplanted into BALB/c nu/nu mice. Once the average tumor volume reached approximately 150 mm3, the mice (N = 4) were treated once daily with sotorasib (100 mg/Kg), or sotorasib plus cetuximab (1 mg/body) for 5 days/week. Data were expressed as the mean ± SD, and the Mann–Whitney U-test was used between the control group and the sotorasib plus cetuximab group.
Fig. 3 KRAS-G12C inhibitor with cetuximab combination showed promising effects in PDCs in 3D and in vivo experiments. a Evaluation of sotorasib plus cetuximab combination efficacy in a 3D culture. b JC288 cells were subcutaneously transplanted into BALB/c nu/nu mice. Once the average tumor volume reached approximately 150 mm3, the mice (N = 4) were treated once daily with sotorasib (100 mg/Kg), or sotorasib plus cetuximab (1 mg/body) for 5 days/week. Data were expressed as the mean ± SD, and the Mann–Whitney U-test was used between the control group and the sotorasib plus cetuximab group.CC BY-NC-ND · PubMed Central
Fig. 4 Her2-PI3K pathway gene alterations were detected in KRAS-G12C inhibitor plus cetuximab combination-resistant PDCs. a Genomic profiling of KRAS-mutated PDCs. Genomic DNA (gDNA) was purified from surgically resected clinical samples, and NGS was executed using 108 cancer-related gene-focused libraries. OncoPlot revealed alterations of the indicated gene (left) in each sample (bottom). b CNV alterations of JC261 cells. The copy ratio was analyzed by CNVkit using target re-sequencing data in Fig. 4a and visualized in the ERBB2 region. c Confirmation of Her2 expression and PI3K signaling. Cell lysates were immunoblotted to detect the indicated antibodies (left).
Fig. 4 Her2-PI3K pathway gene alterations were detected in KRAS-G12C inhibitor plus cetuximab combination-resistant PDCs. a Genomic profiling of KRAS-mutated PDCs. Genomic DNA (gDNA) was purified from surgically resected clinical samples, and NGS was executed using 108 cancer-related gene-focused libraries. OncoPlot revealed alterations of the indicated gene (left) in each sample (bottom). b CNV alterations of JC261 cells. The copy ratio was analyzed by CNVkit using target re-sequencing data in Fig. 4a and visualized in the ERBB2 region. c Confirmation of Her2 expression and PI3K signaling. Cell lysates were immunoblotted to detect the indicated antibodies (left).CC BY-NC-ND · PubMed Central
Fig. 5 Efficacy of dual inhibition of PI3K and mTOR in PIK3CA, ERBB2-amplified KRAS-G12C PDC. a Pharmacological analysis of PI3K pathway inhibitors in JC261 cells. The cells were treated with the indicated 1 µM inhibitors with or without 1 µM of sotorasib for 72 h. Cell viability was analyzed by CellTiter-Glo assay, and the relative cell viability to DMSO treatment was calculated. Data were shown as mean ± SD. b Cell viability analysis of PI3K knockdown and mTOR inhibition. 20 nM of each siRNA was introduced to cells for 48 h. The cell viability was analyzed using the CellTiter-Glo assay, and the relative cell viability to si-control treated condition was calculated. Data were shown as mean ± SD. c Immunoblotting analysis of PI3K, mTOR, and KRAS inhibition. JC261 cells were incubated with the indicated inhibitors. Cell lysates were collected at each time point and immunoblotted to detect the indicated antibodies (left). d Sensitivity to BEZ235 with or without sotorasib (upper) or PP242 with or without GDC0941 and sotorasib in JC261 cells. The cells were treated with the serially diluted BEZ235 or PP242 and the indicated concentration of GDC0941 and sotorasib for 3 days.
Fig. 5 Efficacy of dual inhibition of PI3K and mTOR in PIK3CA, ERBB2-amplified KRAS-G12C PDC. a Pharmacological analysis of PI3K pathway inhibitors in JC261 cells. The cells were treated with the indicated 1 µM inhibitors with or without 1 µM of sotorasib for 72 h. Cell viability was analyzed by CellTiter-Glo assay, and the relative cell viability to DMSO treatment was calculated. Data were shown as mean ± SD. b Cell viability analysis of PI3K knockdown and mTOR inhibition. 20 nM of each siRNA was introduced to cells for 48 h. The cell viability was analyzed using the CellTiter-Glo assay, and the relative cell viability to si-control treated condition was calculated. Data were shown as mean ± SD. c Immunoblotting analysis of PI3K, mTOR, and KRAS inhibition. JC261 cells were incubated with the indicated inhibitors. Cell lysates were collected at each time point and immunoblotted to detect the indicated antibodies (left). d Sensitivity to BEZ235 with or without sotorasib (upper) or PP242 with or without GDC0941 and sotorasib in JC261 cells. The cells were treated with the serially diluted BEZ235 or PP242 and the indicated concentration of GDC0941 and sotorasib for 3 days.CC BY-NC-ND · PubMed Central
Fig. 6 Her2 knockout induced suppression of the Her2-Her3-PI3K pathway and recovered sensitivity to sotorasib. a Certification of Cas9-mediated Her2 knockout. JC261 cells transduced sgHer2 and established Her2 knockout (KO) cell lines. Cell lysates were collected to perform immunoblotting using the indicated antibodies. b Comparison of KRAS downstream signaling between JC261 parent cells and Her2 KO cells in KRAS-G12C inhibition. Cells were exposed to 1 µM of sotorasib each time; cell lysates were then collected and immunoblotted to detect the indicated antibodies. c Evaluation of GTP-KRAS by Ras pull-down assay. Cell lysates were collected, and Ras pull-down assay was performed to detect GTP-KRAS. d Sensitivity to sotorasib in Her2 KO cells. The cells were treated with each concentration of sotorasib for 6 days. e Sensitivity to trametinib in Her2 KO cells. The cells were treated with each concentration of trametinib for 6 days. Cell viability was calculated by CellTiter-Glo assay, and relative cell viability to nontreatment conditions was calculated. Data were shown as mean ± SD.
Fig. 6 Her2 knockout induced suppression of the Her2-Her3-PI3K pathway and recovered sensitivity to sotorasib. a Certification of Cas9-mediated Her2 knockout. JC261 cells transduced sgHer2 and established Her2 knockout (KO) cell lines. Cell lysates were collected to perform immunoblotting using the indicated antibodies. b Comparison of KRAS downstream signaling between JC261 parent cells and Her2 KO cells in KRAS-G12C inhibition. Cells were exposed to 1 µM of sotorasib each time; cell lysates were then collected and immunoblotted to detect the indicated antibodies. c Evaluation of GTP-KRAS by Ras pull-down assay. Cell lysates were collected, and Ras pull-down assay was performed to detect GTP-KRAS. d Sensitivity to sotorasib in Her2 KO cells. The cells were treated with each concentration of sotorasib for 6 days. e Sensitivity to trametinib in Her2 KO cells. The cells were treated with each concentration of trametinib for 6 days. Cell viability was calculated by CellTiter-Glo assay, and relative cell viability to nontreatment conditions was calculated. Data were shown as mean ± SD.CC BY-NC-ND · PubMed Central
Fig. 7 KRAS was mainly localized at the cytoplasm in Her2-positive CRC. a, b Immunofluorescence analysis of KRAS in various cell lines. Representative immunofluorescence images are shown for KRAS (red), E-cadherin, p-Her214, and Hoechst (blue). Scale bar: 20 μm. c Graphical image of Her2-amplified-mediated KRAS localization in this study.
Fig. 7 KRAS was mainly localized at the cytoplasm in Her2-positive CRC. a, b Immunofluorescence analysis of KRAS in various cell lines. Representative immunofluorescence images are shown for KRAS (red), E-cadherin, p-Her214, and Hoechst (blue). Scale bar: 20 μm. c Graphical image of Her2-amplified-mediated KRAS localization in this study.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

15 Valid · 3 Not valid · 1 Not checked · 89 Own results and interpretations

62 more claims · 2 with their cited sources checked

Create a free account to see all 108 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 18
  • It may state two separate claims as one. 29
  • The quote only partly states this claim. 3

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 60 references

Cited by

See all 16

Metadata

Authors
Maruyama, K., Shimizu, Y., Nomura, Y., Oh-hara, T., Takahashi, Y., Nagayama, S., Fujita, N., & Katayama, R.
Affiliations
  • Japanese Foundation For Cancer Research (JP)
  • Toppan (Japan) (JP)
  • Kyoto University (JP)
Corresponding author
Katayama, Ryohei
Venue
npj Precision Oncology
Published
2025-01-06
Volume
9
Issue
1
Pages
4-4
ISSN
2397-768X (ISSN-L)
OpenAlex
W4406083140
Cited by
16
References
60
Citations by year
2026: 9 · 2025: 7
FWCI
6.59
Type
journal article
Language
en
Open access
Licence
Locations
  • npj Precision Oncology (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Japan Agency for Medical Research and Development (JP24ama221210h0003, JP23ama221201h0002, JP24ck0106795h0002)
  • Kobayashi Foundation for Cancer Research (2022SK042)
  • Naito Foundation
  • MEXT | Japan Society for the Promotion of Science (JP22K18383, JP24K02333, JP23KJ0562)
  • Mitsubishi Foundation (N/A)
  • Nippon Foundation (NA)
  • Takeda Science Foundation (NA)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
KRAS inhibitor resistance, KRAS-mutant colorectal cancer, HER2 amplification, PI3K/Akt signaling, PIK3CA mutation, EGFR signaling

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization. https://app.cochat.ai/papers/10.1038/s41698-024-00793-6
The paper
Maruyama, K., Shimizu, Y., Nomura, Y., Oh-hara, T., Takahashi, Y., Nagayama, S., Fujita, N., & Katayama, R. (2025). Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization. npj Precision Oncology. https://doi.org/10.1038/s41698-024-00793-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.